Positive News SentimentPositive NewsNASDAQ:APRE Aprea Therapeutics (APRE) Stock Price, News & Analysis $1.87 -0.06 (-2.90%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aprea Therapeutics Stock (NASDAQ:APRE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aprea Therapeutics alerts:Sign Up Key Stats Today's Range$1.86▼$2.0050-Day Range$1.60▼$2.0852-Week Range$1.41▼$5.01Volume14,711 shsAverage Volume35,754 shsMarket Capitalization$10.36 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company Overview Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania. Read More Aprea Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreAPRE MarketRank™: Aprea Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 450th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aprea Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.55) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aprea Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.64% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.64% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentAprea Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aprea Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.63% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.19% of the stock of Aprea Therapeutics is held by institutions.Read more about Aprea Therapeutics' insider trading history. Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APRE Stock News HeadlinesAprea Therapeutics Inc (APRE) - Investing.comJune 29, 2025 | investing.comAprea Therapeutics, Inc. (APRE) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 25 at 2:00 AM | Paradigm Press (Ad)Aprea Therapeutics Reports Promising Preclinical and Initial Clinical Data for APR-1051 in HPV+ Head and Neck Cancers - NasdaqJune 26, 2025 | nasdaq.comAprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive CancersJune 26, 2025 | msn.comPleasing Signs As A Number Of Insiders Buy Aprea Therapeutics StockJune 25, 2025 | finance.yahoo.comAprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer CenterJune 25, 2025 | globenewswire.comAprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical UpdateMay 14, 2025 | globenewswire.comSee More Headlines APRE Stock Analysis - Frequently Asked Questions How have APRE shares performed this year? Aprea Therapeutics' stock was trading at $3.29 at the beginning of 2025. Since then, APRE shares have decreased by 40.2% and is now trading at $1.9690. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.01. The company had revenue of $0.16 million for the quarter. Aprea Therapeutics had a negative net margin of 1,095.02% and a negative trailing twelve-month return on equity of 68.39%. When did Aprea Therapeutics' stock split? Aprea Therapeutics's stock reverse split before market open on Monday, February 13th 2023.The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aprea Therapeutics IPO? Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings5/14/2025Today7/25/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APRE CIK1781983 Webwww.aprea.com Phone617-463-9385FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Aprea Therapeutics$15.50 High Price Target$20.00 Low Price Target$11.00 Potential Upside/Downside+703.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.96 million Net Margins-1,095.02% Pretax Margin-1,095.02% Return on Equity-68.39% Return on Assets-55.74% Debt Debt-to-Equity RatioN/A Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual Sales$1.50 million Price / Sales7.12 Cash FlowN/A Price / Cash FlowN/A Book Value$3.55 per share Price / Book0.54Miscellaneous Outstanding Shares5,530,000Free Float4,777,000Market Cap$10.67 million OptionableNo Data Beta1.19 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:APRE) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.